Table 3 Patients’ general information.
Low-to-medium risk group (n = 12) | High-to-extremely-high risk group (n = 89) | P | |
|---|---|---|---|
Gender | 7:5 | 58:31 | 0.643 |
Age | 46.08 ± 14.21 | 52.55 ± 12.54 | 0.102 |
Hypertension | 3/12 | 57/89 | 0.010 |
Diabetes | 1/12 | 18/89 | 0.322 |
Proteinuria | 3.41 ± 1.81 | 5.61 ± 1.90 | 0.000 |
Serum albumin | 30.20 ± 4.27 | 20.89 ± 3.86 | 0.000 |
Serum creatinine | 79.05 ± 19.75 | 88.06 ± 59.13 | 0.603 |
EGFR | 94.95 ± 14.77 | 88.52 ± 25.76 | 0.401 |
PLA2R-IgG(TRFIA) | 65.15 ± 96.37 | 158.83 ± 199.37 | 0.113 |
PLA2R-IgG4(TRFIA) | 2295.52 ± 3774.05 | 6503.96 ± 6940.21 | 0.043 |
PLA2R-CySR-IgG(TRFIA) | 30.39 ± 38.83 | 87.74 ± 150.49 | 0.194 |
PLA2R-CySR-IgG4(TRFIA) | 725.45 ± 1380.93 | 2194.48 ± 6495.32 | 0.068 |
PLA2R-CTLD1-IgG(TRFIA) | 16.17 ± 23.60 | 43.09 ± 84.39 | 0.276 |
PLA2R-CTLD1-IgG4(TRFIA) | 305.11 ± 852.08 | 478.83 ± 1181.35 | 0.628 |
PLA2R-CTLD678-IgG(TRFIA) | 18.54 ± 25.69 | 118.93 ± 376.76 | 0.360 |
PLA2R-CTLD678-IgG4(TRFIA) | 273.12 ± 597.78 | 2548.87 ± 6198.85 | 0.001 |
IgG Epitope spreading | 5/12 | 65/89 | 0.027 |
IgG4 Epitope spreading | 6/12 | 74/89 | 0.008 |
